Pathological gambling caused by drugs used to treat Parkinson disease
- PMID: 16009751
- DOI: 10.1001/archneur.62.9.noc50009
Pathological gambling caused by drugs used to treat Parkinson disease
Abstract
Background: Pathological gambling is a rare potential complication related to treatment of Parkinson disease (PD). However, the etiology of this behavior is poorly understood.
Objective: To examine the relationship between medical therapy for PD and pathological gambling.
Methods: In our routine movement disorders practice (2002-2004), we encountered 11 patients with idiopathic PD who had recently developed pathological gambling. We assessed the relationship to their medical therapy and compared them with cases identified by systematic review of the existing literature on pathological gambling and PD.
Results: All 11 patients with PD and pathological gambling were taking therapeutic doses of a dopamine agonist; 3 of these patients were not treated with levodopa. In 7 patients, pathological gambling developed within 3 months of starting to take or escalating the dose of the agonist; in the other 4 with a longer latency, gambling resolved after the agonist use was discontinued. Pramipexole dihydrochloride was the agonist in 9 of 11 cases in our series and 10 of 17 in the literature (68% in total).
Conclusions: Dopamine agonist therapy was associated with potentially reversible pathological gambling, and pramipexole was the medication predominantly implicated. This may relate to disproportionate stimulation of dopamine D(3) receptors, which are primarily localized to the limbic system.
Comment in
-
Impulse control disorders and dopaminergic drugs.Arch Neurol. 2006 Feb;63(2):298-9; author reply 299. doi: 10.1001/archneur.63.2.298-b. Arch Neurol. 2006. PMID: 16476826 No abstract available.
-
Gambling and Parkinson disease.Arch Neurol. 2006 Feb;63(2):298. doi: 10.1001/archneur.63.2.298-a. Arch Neurol. 2006. PMID: 16476827 No abstract available.
-
Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database.Arch Neurol. 2006 Feb;63(2):299-300; author reply 300. doi: 10.1001/archneur.63.2.299-b. Arch Neurol. 2006. PMID: 16476828 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
